Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New insights on TNF blockers alone for early arthritis

NCT ID NCT02927535

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study followed 813 people with early rheumatoid arthritis in France to see how often doctors prescribe TNF blockers alone (without other arthritis drugs) and how well they work. Researchers tracked symptoms, joint damage, and how long patients stayed on treatment over 5 years. The goal is to learn which patients might benefit most from this approach.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TNF blockers (a type of drug that blocks inflammation)
What this could lead to
If successful, this study could help doctors better understand when to use TNF blockers alone for early rheumatoid arthritis, potentially improving treatment decisions.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient differences and real-world factors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

813 people

The number who actually took part.

Started

Jan 2016

Finished

Dec 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients in the ESPOIR cohort (multicentre French cohort study of early RA). A sub-analysis will be conducted among patients satisfying the ACR-EULAR 2010 criteria.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age 18 to 70 years * more than 2 swollen joints for \>6 weeks and \<6 months * suspected or confirmed diagnosis of RA * no previous intake of DMARDs or steroids (except if \<2 weeks). Exclusion Criteria: * Patients were excluded if the referring physician judged they had other clearly defined inflammatory rheumatic diseases.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rheumatoid arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rheumatoid arthritis

Contacts and locations

Locations

  • CHU de Nîmes

    Nîmes, 30029, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.